contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vicore-presenterar-pa-dnb-carnegie-nordic-healthcare-conference

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vicore Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

Vicore Pharma Holding

Stockholm, 20 november 2025 – Vicore Pharma Holding AB (publ) (STO: VICO), ett läkemedelsbolag i klinisk fas som utvecklar en ny klass av läkemedel, angiotensin II typ 2-receptor agonister (...

<div class="mfn-body">Stockholm, 20 november 2025 – Vicore Pharma Holding AB (publ) (STO: VICO), ett läkemedelsbolag i klinisk fas som utvecklar en ny klass av läkemedel, angiotensin II typ 2-receptor agonister (ATRAGs), meddelar idag att bolaget medverkar på DNB Carnegie Nordic Healthcare Conference den 25 november.&nbsp;<ul><li>Plats: Oslo, Norge&nbsp;</li><li>Format: Presentation och 1×1 möten&nbsp;</li><li>Presentation, datum och tid: Tisdag 25 november kl. 15:35 CET&nbsp;</li><li>Medverkande: Hans Jeppsson, CFO&nbsp;</li></ul>Bolagets ledning kommer finnas tillgänglig för möten under konferensen.&nbsp;För ytterligare information, vänligen kontakta:&nbsp; Megan Richards, VP Investor Relations, Communications and Portfolio Strategy, tel: +1 978 269-4372, <a rel="noopener" href="mailto:megan.richards@vicorepharma.com">megan.richards@vicorepharma.com</a>&nbsp; Hans Jeppsson, CFO, tel: 070 553 14 65, <a rel="noopener" href="mailto:hans.jeppsson@vicorepharma.com">hans.jeppsson@vicorepharma.com</a>&nbsp; &nbsp; Om Vicore Pharma&nbsp; Vicore Pharma Holding AB (publ) är ett läkemedelsbolag i klinisk fas som utvecklar en ny klass av läkemedel med sjukdomsmodifierande potential inom respiratoriska och fibrotiska sjukdomar, inklusive idiopatisk lungfibros (IPF). Bolagets främsta program, buloxibutid (C21), är en oralt administrerad småmolekylär ”first-in-class” angiotensin II typ 2-receptor agonist (ATRAG) som har erhållit särläkemedelsstatus (Orphan Drug) och Fast Track Designation från den amerikanska läkemedelsmyndigheten FDA. Buloxibutid utvärderas i den pågående globala 52-veckors fas 2b-studien ASPIRE-studien i IPF.&nbsp;Bolagets aktie (VICO) är noterad på Nasdaq Stockholms huvudlista. <a rel="noopener" href="http://www.vicorepharma.com/">www.vicorepharma.com</a>&nbsp;</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Bifogade filer <a rel="noopener" href="https://storage.mfn.se/72b17991-012e-47f9-a4e3-733527c81ae0/vicore-presenterar-pa-dnb-carnegie-nordic-healthcare-conference.pdf" class="mfn-generated mfn-primary">Vicore presenterar på DNB Carnegie Nordic Healthcare Conference</a></div>